A phase II trial of second‐line axitinib following prior antiangiogenic therapy in advanced hepatocellular carcinoma

Abstract

With 42.3% tumor control at 16 weeks, primary endpoint was met. Axitinib has shown encouraging tolerable clinical activity in VEGF-pretreated HCC patients but further study should be in a selected population incorporating potential biomarkers of response.